$2.54T
Total marketcap
$193.21B
Total volume
BTC 49.92%     ETH 15.85%
Dominance

BioMarin Pharmaceutical BMRN Stock

83.81 USD {{ price }} -0.071545% {{change_pct}}%
Exchange
NasdaqGS
Market Cap
15.81B USD
LOW - HIGH [24H]
83.66 - 84.67 USD
VOLUME [24H]
1.4M USD
{{ volume }}
P/E Ratio
96.33
Earnings per share
0.87 USD

BioMarin Pharmaceutical Price Chart

BioMarin Pharmaceutical BMRN Financial and Trading Overview

BioMarin Pharmaceutical stock price 83.81 USD
Previous Close 94.41 USD
Open 94 USD
Bid 0 USD x 800
Ask 0 USD x 1300
Day's Range 93.96 - 96.35 USD
52 Week Range 72.22 - 117.77 USD
Volume 960.86K USD
Avg. Volume 1.06M USD
Market Cap 17.99B USD
Beta (5Y Monthly) 0.382042
PE Ratio (TTM) 259.027
EPS (TTM) 0.87 USD
Forward Dividend & Yield N/A (N/A)
Ex-Dividend Date N/A
1y Target Est 119.77 USD

BMRN Valuation Measures

Enterprise Value 17.93B USD
Trailing P/E 259.027
Forward P/E 33.51049
PEG Ratio (5 yr expected) 1.64
Price/Sales (ttm) 8.278176
Price/Book (mrq) 3.8590698
Enterprise Value/Revenue 8.251
Enterprise Value/EBITDA 101.222

Trading Information

BioMarin Pharmaceutical Stock Price History

Beta (5Y Monthly) 0.382042
52-Week Change 25.97%
S&P500 52-Week Change 20.43%
52 Week High 117.77 USD
52 Week Low 72.22 USD
50-Day Moving Average 94.28 USD
200-Day Moving Average 96.32 USD

BMRN Share Statistics

Avg. Volume (3 month) 1.06M USD
Avg. Daily Volume (10-Days) 938.58K USD
Shares Outstanding 187.7M
Float 186.28M
Short Ratio 7.04
% Held by Insiders 0.47%
% Held by Institutions 100.41%
Shares Short 6.73M
Short % of Float 3.59%
Short % of Shares Outstanding 3.59%

Dividends & Splits

Trailing Annual Dividend Rate 0
Trailing Annual Dividend Yield 0%
5 Year Average Dividend Yield N/A
Payout Ratio 0
Last Split Factor

Financial Highlights

Fiscal Year

Fiscal Year Ends December 31, 2022
Most Recent Quarter (mrq) March 31, 2023
Next Fiscal Year End December 31, 2023

Profitability

Profit Margin 3.29%
Operating Margin (ttm) 3.50%
Gross Margin 46.90%
EBITDA Margin 8.15%

Management Effectiveness

Return on Assets (ttm) 0.76%
Return on Equity (ttm) 1.58%

Income Statement

Revenue (ttm) 2.17B USD
Revenue Per Share (ttm) 11.69 USD
Quarterly Revenue Growth (yoy) 14.79%
Gross Profit (ttm) 1.61B USD
EBITDA 177.14M USD
Net Income Avi to Common (ttm) 71.62M USD
Diluted EPS (ttm) 0.37
Quarterly Earnings Growth (yoy) -57.89%

Balance Sheet

Total Cash (mrq) 1.15B USD
Total Cash Per Share (mrq) 6.14 USD
Total Debt (mrq) 1.09B USD
Total Debt/Equity (mrq) 23.47 USD
Current Ratio (mrq) 4.751
Book Value Per Share (mrq) 24.835

Cash Flow Statement

Operating Cash Flow (ttm) 147.4M USD
Levered Free Cash Flow (ttm) -27610376 USD

Profile of BioMarin Pharmaceutical

Country United States
State CA
City San Rafael
Address 770 Lindaro Street
ZIP 94901
Phone 415 506 6700
Website https://www.biomarin.com
Industry Biotechnology
Sector(s) Healthcare
Full Time Employees 3082

BioMarin Pharmaceutical Inc. develops and commercializes therapies for people with serious and life-threatening rare diseases and medical conditions. Its commercial products include Vimizim, an enzyme replacement therapy for the treatment of mucopolysaccharidosis (MPS) IV type A, a lysosomal storage disorder; Naglazyme, a recombinant form of N-acetylgalactosamine 4-sulfatase for patients with MPS VI; and Kuvan, a proprietary synthetic oral form of 6R-BH4 that is used to treat patients with phenylketonuria (PKU), an inherited metabolic disease. The company's commercial products also comprise Palynziq, a PEGylated recombinant phenylalanine ammonia lyase enzyme, which is delivered through subcutaneous injection to reduce blood Phe concentrations; Brineura, a recombinant human tripeptidyl peptidase 1 for the treatment of patients with ceroid lipofuscinosis type 2, a form of Batten disease; Voxzogo, a once daily injection analog of c-type natriuretic peptide for the treatment of achondroplasia; and Aldurazyme, a purified protein designed to be identical to a naturally occurring form of the human enzyme alpha-L-iduronidase. In addition, it develops Roctavian, an adeno associated virus vector, for the treatment of patients with severe hemophilia A; BMN 331, an AAV5 mediated gene therapy, which is in Phase 1/2 clinical trial for people living with Hereditary Angioedema (HAE); and BMN 255 that is in Phase 1/2 clinical trial for treating primary hyperoxaluria. The company serves specialty pharmacies, hospitals, and non-U.S. government agencies, as well as distributors and pharmaceutical wholesalers in the United States, Europe, Latin America, and internationally. BioMarin Pharmaceutical Inc. has license and collaboration agreements with Sarepta Therapeutics, Ares Trading S.A., Catalyst Pharmaceutical Partners, Inc., and Asubio Pharma Co., Ltd. The company was incorporated in 1996 and is headquartered in San Rafael, California.

Q&A For BioMarin Pharmaceutical Stock

What is a current BMRN stock price?

BioMarin Pharmaceutical BMRN stock price today per share is 83.81 USD.

How to purchase BioMarin Pharmaceutical stock?

You can buy BMRN shares on the NasdaqGS exchange. Contact your financial advisor to select a broker.

What is the ticker symbol for BioMarin Pharmaceutical?

The stock symbol or ticker of BioMarin Pharmaceutical is BMRN.

Which industry does the BioMarin Pharmaceutical company belong to?

The BioMarin Pharmaceutical industry is Biotechnology.

How many shares does BioMarin Pharmaceutical have in circulation?

The max supply of BioMarin Pharmaceutical shares is 188.68M.

What is BioMarin Pharmaceutical Price to Earnings Ratio (PE Ratio)?

BioMarin Pharmaceutical PE Ratio is 96.33333000 now.

What was BioMarin Pharmaceutical earnings per share over the trailing 12 months (TTM)?

BioMarin Pharmaceutical EPS is 0.87 USD over the trailing 12 months.

Which sector does the BioMarin Pharmaceutical company belong to?

The BioMarin Pharmaceutical sector is Healthcare.

BioMarin Pharmaceutical BMRN included in indexes

Name Name Price Price 24h%
7d chart
24h% & 7d
VOL Volume 24h low 24h high Volume
Name Name Price Price 24h%
7d chart
24h% & 7d
VOL Volume 24h low 24h high Volume
{{ item.name }} {{ item.symbol }} {{ item.price }} {{ item.price_usd }}
{{ item.change_pct }}
{{ item.volume }} {{ item.volume_usd }} {{ item.low }} {{ item.low_usd }} {{ item.high }} {{ item.high_usd }} {{ item.components_count }} {{ item.volume }} {{ item.volume_usd }}
NASDAQ Composite IXIC 16103.45 USD
+0.82
4.52B USD 16094.17 USD 16247.59 USD 4.52B USD
Dow Jones U.S. Biotechnology In DJUSBT 2844.59 USD
+0.08
79.29M USD 2839.63 USD 2860.51 USD 79.29M USD
NASDAQ Biotechnology Total Retu XNBI 4654.3 USD
-0.65
4652.69 USD 4696.7 USD
NASDAQ Q 50 NXTQ 737.55 USD
-0.27
737.3 USD 745.3 USD
NASDAQ Global Select Market Com NQGS 7837.41 USD
+0.85
7832.7 USD 7908.95 USD
Nasdaq Next Generation 100 Inde NGX 1138.09 USD
-0.13
1137.73 USD 1146.36 USD
NASDAQ Biotechnology NBI 4337.34 USD
-0.65
4335.84 USD 4376.86 USD
NASDAQ HealthCare IXHC 986.88 USD
-0.25
986.44 USD 994.67 USD
NASDAQ Composite Total Return I XCMP 19565.06 USD
+0.82
19553.78 USD 19740.18 USD
Nasdaq US Smart Pharmaceuticals NQSSPH 1454.2 USD
-0.47
1453.71 USD 1464.83 USD
NASDAQ DM Ex Japan Large Mid Ca NQDMXJPLMAUD 2100.38 AUD 1390.15 USD
<0.01
2100.38 AUD 1390.15 USD 2100.38 AUD 1390.15 USD
Stlmt ID NASDAQ Biotechnology NBX 4604.4 USD
-2.98
4555.41 USD 4917.8 USD